LGND News and Press, Ligand Pharmaceuticals Incorporated From 04/16/24

2024-04-16 07:20:23 ET Reporting its Q1 2024 results, Big Pharma’s earnings bellwether, Johnson & Johnson ( NYSE: JNJ ), revised its full-year outlook below consensus on Tuesday after sales from its MedTech division fell short of Street forecasts.... Read the full a...

2024-04-12 23:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Captisol-enabled™ Topiramate Injection shown to be a substitute for an oral dose on a one-to-one basis Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partners at the University of Minnesota (UMN) and CURx Pharmaceuticals, Inc. presented new data on Ca...

2024-04-05 13:53:08 ET More on Ovid Therapeutics Seeking Alpha’s Quant Rating on Ovid Therapeutics Historical earnings data for Ovid Therapeutics Financial information for Ovid Therapeutics Read the full article on Seeking Alpha For further det...

2024-04-03 09:23:59 ET More on Ligand Pharmaceuticals Ligand Pharmaceuticals Inc. (LGND) Q4 2023 Earnings Call Transcript Ligand Pharmaceuticals gains amid bullish investor pitch Ligand Pharmaceuticals Non-GAAP EPS of $1.05 beats by $0.39, revenue of $28.1M beats by ...

Pharmaceutical executive Scott Plesha named CEO Lead product ZELSUVMI expected to be commercially available in late 2024 Ligand Pharmaceuticals (Nasdaq: LGND) today announced the launch of Pelthos Therapeutics (Pelthos), a biopharmaceutical company, and the appointment of season...

2024-04-02 06:01:11 ET Summary Viking Therapeutics' share price has rapidly increased from recent weight loss drug excitement. The company’s value seems to be derived from its weight loss and NASH/MASH candidates. VK2735, the weight loss candidate, presents a potentiall...

2024-03-27 15:53:27 ET More on Ligand Pharmaceuticals Ligand Pharmaceuticals Inc. (LGND) Q4 2023 Earnings Call Transcript Ligand Pharmaceuticals Non-GAAP EPS of $1.05 beats by $0.39, revenue of $28.1M beats by $2.46M Ligand Pharmaceuticals Q4 2023 Earnings Preview ...

2024-03-24 00:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-13 22:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...